Neurocrine Biosciences (NBIX) Form 4 NEUROCRINE BIOSCIENCES / EIRY ROBERTS ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

ROBERTS EIRY

(Last) (First) (Middle)

12780 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/07/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/07/2023		M		38,722	A	$77.81	68,243	D
Common Stock	12/07/2023		S(1)		38,722	D	$120.3739(2)	29,521	D
Common Stock	12/07/2023		M		12,742	A	$77.81	42,263	D
Common Stock	12/07/2023		S(1)		12,742	D	$120.3715(3)	29,521	D
Common Stock	12/07/2023		M		14,140	A	$79.02	43,661	D
Common Stock	12/07/2023		S(1)		14,140	D	$120.3715(3)	29,521	D
Common Stock	12/07/2023		M		11,775	A	$81.05	41,296	D
Common Stock	12/07/2023		S(1)		11,775	D	$120.3715(3)	29,521	D
Common Stock	12/08/2023		M		200	A	$81.05	29,721	D
Common Stock	12/08/2023		S(1)		200	D	$120.155(4)	29,521	D
Common Stock	12/08/2023		M		100	A	$81.05	29,621	D
Common Stock	12/08/2023		S(1)		100	D	$120	29,521(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$77.81	12/07/2023		M			38,722	(6)	01/08/2028	Common Stock	38,722	$77.81	12,742	D
Non-Qualified Stock Option	$77.81	12/07/2023		M			12,742	(6)	01/08/2028	Common Stock	12,742	$77.81	0	D
Non-Qualified Stock Option	$79.02	12/07/2023		M			14,140	(7)	01/31/2032	Common Stock	14,140	$79.02	60,005	D
Non-Qualified Stock Option	$81.05	12/07/2023		M			11,775	(8)	02/07/2029	Common Stock	11,775	$81.05	53,665	D
Non-Qualified Stock Option	$81.05	12/08/2023		M			200	(8)	02/07/2029	Common Stock	200	$81.05	53,465	D
Non-Qualified Stock Option	$81.05	12/08/2023		M			100	(8)	02/02/2029	Common Stock	100	$81.05	53,365	D

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. 28,366 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

6. Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019.

7. Option granted January 31, 2022 and vested monthly over four years.

8. Option granted February 7, 2019 and vested monthly over four years.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	12/11/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.